NCT00197951

Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism

Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology, Not Being a Severe Mental Disorder, Associated to Alcohol Dependence Disorder.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (planned)
• Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of dopamine, norepinephrine and serotonin neurotransmission, during early recovery. Ziprasidone can improve malfunctioning of these disregulated systems, thereby improving anxiety, depression, anhedonia, anger, and alcohol craving.

Detailed description

60 alcohol-dependent patients will be included, once finished alcohol detoxification treatment.Thirty patients will receive ziprasidone treatment, in progressively increasing doses, starting from 40 mg per day, and the other 30 patients will receive placebo, in a double blind procedure

Conditions

• Depression
• Anger
• Anxiety
• Alcoholism

Interventions

Type	Name	Description
DRUG	Treatment of psychiatric symptoms associated to alcoholism

Timeline

• Start date: 2004-10-01
• Completion: 2007-04-01
• First posted: 2005-09-20
• Last updated: 2007-04-23

Locations

1 site across 1 country: Spain